The federal right-to-try law was a prime topic for conversation at the recent 2018 BIO International Convention in Boston, coming just days after President Trump signed the measure that creates a new pathway for preapproval access to investigational medicines.
The Pink Sheet spoke with the CEOs of Alnylam Pharmaceuticals Inc. and Sarepta Therapeutics Inc., two biotech companies...